louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06747819: Effect of Cervical Epidural Steroid Injection With Neural Mobilization in Patients With Cervical Radicular Pain
Official title: Effect of Cervical Epidural Steroid Injection With Neural Mobilization in Patients With Cervical Radicular Pain
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Cervical Pain
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2024-12-24
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study examines the effectiveness of cervical epidural steroid injections (CESI) and neural mobilization (NM), individually and in combination, in alleviating cervical radicular pain-a condition characterized by nerve root compression or irritation often due to herniated discs or bony spurs. Cervical radiculopathy leads to chronic pain, sensory and motor deficits, and disability in the upper limbs.

Detailed description: The study is a randomized controlled trial conducted between April and October 2024, with patients diagnosed with cervical radicular pain randomized into three groups: CESI-only, NM-only, and combined CESI and NM.

Eligibility criteria: Inclusion Criteria:

* Adults aged 18-65 years, diagnosed with chronic cervical radicular pain.
* Patients with chronic cervical radicular pain (\>6 months).
* Patients who had been confirmed through clinical examination and imaging studies (MRI or CT) showed evidence of nerve root compression.
* Participants were included if they provided written informed consent, demonstrated the ability to adhere to the study protocol, and committed to attending follow-up appointments while completing the required outcome measures.

Exclusion Criteria:

* Patient refusal.
* Patients above the age of 65 were eliminated to reduce confounding by age-related health concerns and to provide a more homogenous study population for more accurate treatment outcomes.
* Patients with a history of cervical spine surgery, Uncontrolled Diabetes Mellitus, Hypertension Ischemic Heart Disease, and Pregnancy
* Patients with chronic pain syndromes that may interfere with cervical radicular pain evaluation, such as fibromyalgia, rheumatoid arthritis, or hypersensitivity, will be excluded. These disorders will be evaluated during screening using a complete medical history review, physical examination, and precise diagnostic criteria to guarantee correct detection of cervical radicular discomfort.

Primary outcomes:
measure: Numeric Pain Rating Scale (NPRS)
timeFrame: 12 Months
measure: The Neck Disability Index (NDI)
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Ghurki trust and teaching hospital
state: Punjab
Study officials:
References:
Clinical trial NCT04983719: Transcervical Myoma Biopsy Video
Official title: Fertility-sparing Management of a Suspicion of Leiomyosarcoma: Avoiding Hysterectomy by Performing Transcervical Myoma Biopsy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atypical
Myoma
Keywords: YOUNG WOMAN WITH DESIRE FOR PREGNANCY
ATYPICAL MYOMA
FERTILITY PRESERVATION
BIOPSY
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2021-07-30
Enrollment: 1
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: YOUNG WOMAN WITH DESIRE FOR PREGNANCY AND ATYPICAL MYOMA

Brief summary: To describe the fertility-sparing management of an atypical uterine myoma. Step-by-step video explanation of transcervical biopsy using transabdominal ultrasound guidance, highlighting tips and tricks. Patient consent was obtained for publication of the case.


Eligibility criteria: Inclusion criteria:

* age \>18 years old
* WOMAN WITH DESIRE FOR PREGNANCY
* ATYPICAL MYOMA

Exclusion criteria:

- age \< 18 years old

Primary outcomes:
measure: Evaluation of video
timeFrame: day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: GAUTHIER RATHAT, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00646919: Preoperative Nasal Swabs From Pediatric Patients
Official title: Double-Blind Prospective Study Concerning the Connection Between Positive Nasal Culture for Staphyloccoci in Pediatric Patients Undergoing Any Elective Surgery in the Out-Patient Clinic in the Hillel Yaffe Medical Center, Over a Period of One Year
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Staphylococcal Infections
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2008-03-31
Sex: ALL
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All pediatric patients attending our outpatient surgery clinic

Brief summary: We intend to take a nasal swab from each pediatric pre-operative patient in our out-clinic with the intention of looking for a connection between positive operative incisions and a positive nasal swab. The patients will be in the out-patient clinic for a few hours, and will be examined post-operatively after one week. Those with positive nasal swabs will be advised to apply a nasal cream (Mupirocin)in their noses for one week. Our hypothesis is that there is a correlation between positive nasal swabs and positive incision infections.


Eligibility criteria: Inclusion Criteria:

* All pediatric patients attending outpatient surgery clinic

Exclusion Criteria:

* All others

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
References:
Clinical trial NCT00418119: Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function
Official title: Phase 4 Study on the Efficacy of Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Heart Failure
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2007-01-04
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Erythropoietin Treatment in Patients with systolic left ventricular dysfunction, mild anemia and normal renal function


Eligibility criteria: Inclusion Criteria:

* Ischemic heart disease
* Systolic lv dysfunction
* Mild anemia
* Normal renal function
* Stable condition

Exclusion Criteria:

* Pregnancy
* Unstable condition
* Under 18 years old

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Petah Tikva
country: Israel
facility: Cardiology Department, Rabin Medical Center
Study officials:
affiliation: Cardiology Department Rabin medical Center
name: Tuvia Ben Gal, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hematology Department Rabin Medical Center
name: Ofer Shpilberg, Prof.
role: STUDY_DIRECTOR
affiliation: Cardiology Department Rabin Medical Center
name: Daniel Murninkas, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01907919: Pilot Study,Diode Laser 808 nm Supported Direct Pulp Capping in Permanent Teeth
Official title: Diode Laser-Assisted Direct Pulp Capping In Permanent Teeth
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Haemostatic
Bacterial De-contamination
Bio-stimulation
Reparative Dentine Formation
Pain Reduction
Keywords: Pulp capping, Diode laser 808 nm, Tertiary dentin, RM-GIC
Lead sponsor: Yazdanfar, Iraj, M.D.
Sponsor class: INDIV
Collaborators: name: RWTH Aachen University
First posted: 2013-07-25
Enrollment: 10
Sex: ALL
Minimum age (years): 12
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study was carried out on 10 patients, aged between 12 and 40 years, with an average age of 26 years, who underwent conservative treatment for deep caries of permanent teeth (2 anterior and 8 posterior).

Brief summary: The purpose of this study was to compare the conventional and diode 808 nm laser-assisted techniques in direct pulp capping in permanent teeth .The present study was based on a series of ten clinical studies with pulp exposure caused by carious lesions.The hypothesis of this paper was laser supported direct pulp cap-ping has proven effectiveness by its capacity to stimulate reparative dentine formation by pulp cells, de-contamination ability of irradiated areas, its ability in the fast and better haemostatic, and pain reduction.


Eligibility criteria: Inclusion Criteria:

1. Permanent teeth with deep caries
2. Vitality of teeth
3. No peri-apical radiographic changes
4. Acceptance research program

Exclusion Criteria:

1. Symptoms
2. Peri-apical radiographic changes
3. No stopped bleeding within 3 minutes after exposure
4. No acceptance study program

Primary outcomes:
measure: Maintenance of teeth vitality was be measured via thermal tests also by radiographic.
timeFrame: up to 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01563419: Clinical Usefulness of a Magnifier for Insulin Pen
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus
Keywords: Insulin
Diabetes
Low vision
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2012-03-27
Enrollment: 50
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Insulin treatment is crucial for glucose control. Many patients with type 2 diabetes exhibit inadequate glycemic control in spite of combination of oral antidiabetic drugs and eventually need insulin therapy. Patients who need insulin therapy are older and have poor visual acuity, which predispose to inaccurate dosing and consequent hyper or hypoglycemia.In this study, the investigators examined the clinical usefulness of a magnifier for elderly diabetic patients who had used insulin pens.


Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of diabetes mellitus
* over 60 years old
* who have self-injected insulin with insulin pens

Exclusion Criteria:

* who have visual acuity less than 20/200 for each eye
* who had surgery on his/her eyes within a week

Primary outcomes:
measure: the time spent to complete dialing up insulin pens
timeFrame: from to start dialing up the selected dose to to complete dialing up, assessed up to 10 minutes
Secondary outcomes:
measure: the dosing accuracy
timeFrame: from to start dialing up the selected dose to to complete dialing up, assessed up to 10 minutes
measure: the convenience in using insulin pens
timeFrame: the duration of to complete filling up the questionnaires, an expected average of 10 minutes
measure: the self-confidence in using insulin pens
timeFrame: the duration of to complete filling up the questionnaires, an expected average of 10 minutes
measure: the need for glasses in using insulin pens
timeFrame: the duration of to complete filling up the questionnaires, an expected average of 10 minutes
measure: the preferences for the use of a magnifier
timeFrame: the duration of to complete filling up the questionnaires, an expected average of 10 minutes
measure: the recommendation for the use of a magnifier
timeFrame: the duration of to complete filling up the questionnaires, an expected average of 10 minutes
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University College of Medicine
name: Young Min Cho, MD,PhD
role: STUDY_CHAIR
References:
Clinical trial NCT02906319: Vitamin D and HbA1c Levels in Diabetic Patients With CKD
Official title: Association Between Serum 25-hydroxyvitamin D Levels and Glycated Haemoglobin in Diabetic Patients With Chronic Kidney Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Vitamin D Deficiency
Diabetes Mellitus
Lead sponsor: University of Malaya
Sponsor class: OTHER
Collaborators: name: University of Malaya
name: Malaysian Society of Nephrology
First posted: 2016-09-20
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who attended specialized diabetic, renal, and general outpatient clinics in the University of Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia.

Brief summary: The purpose of this study is to determine the association between serum 25-hydroxyvitamin D and HbA1c levels in diabetic patients with chronic kidney disease. The investigators hypothesized that serum 25-hydroxyvitamin D levels were negatively correlated with HbA1c levels.

Detailed description: This was a cross sectional study using consecutive sampling methodology for participant recruitment. It was carried out at the specialized diabetic, renal, and general outpatient clinics in the University of Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia.

Serum 25(OH)D levels were determined by using direct chemiluminesent immunoassay (ADVIA Centaur XP; Siemens Healthcare Diagnostics, Tarrytown, New York, USA). Serum HbA1c levels were determined using high-pressure liquid chromatography (Variant™ II Turbo; Bio-Rad, Hercules, California, USA).

Data collected will be analyzed using Statistical Package for Social Sciences SPSS version 23.0 for Windows, version 23.0 (IBM Corp., Armonk, New York, USA).

Eligibility criteria: Inclusion Criteria:

* eGFR 15-59 ml/min/1.73m2
* age ≥ 18 years old
* able to provide informed consent

Exclusion Criteria:

* active infections
* autoimmune diseases
* malignancies
* on immunosuppressive therapy
* on vitamin D supplements

Primary outcomes:
measure: 25-hydroxyvitamin D levels
timeFrame: Within 2 weeks from enrolment
measure: HbA1c levels
timeFrame: Within 2 weeks from enrolment
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Malaya
name: Yong Muh Ng, MMed
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04996719: Effect of Rapamycin to Improve Cardiac Function in Frail Older Adults
Official title: Effect of Rapamycin to Improve Cardiac Function in Frail Older Adults With Heart Failure With Preserved Ejection Fraction: A Randomized Pilot and Proof-of-Concept Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Heart Failure
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-08-09
Enrollment: 24
Sex: ALL
Minimum age (years): 60
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this research is to see if the drug rapamycin will improve the heart's ability to pump by improving your oxygen consumption.

Detailed description: This will be a pilot, proof-of-concept study. Patients 60 years or older with invasively proven HFpEF or have definite HFpEF as determined by the 2 established scores and frailty (positive screen for computable phenotype), will be approached for enrollment. Subjects meeting screening criteria following written informed consent will be randomized to receive rapamycin or matching placebo (study drug). Efficacy outcomes will be measured at baseline and at 6 months. Safety will be assessed by in person or remote video monitoring weekly for 1 month, then monthly for 5 months till the end of the study. We will also measure trough rapamycin levels (≤4ng/mL) twice-a-month for the first month and then monthly for 5 months.

Eligibility criteria: Inclusion Criteria:

* Age ≥60 years
* Diagnosis of HFpEF by either H2FEPF score of 6-9 or HFA-PEFF score of 5-6, or invasively confirmed diagnosis of HFpEF (resting pulmonary capillary wedge pressure ≥15mmHg or ≥25mmHg with exercise).
* Diagnosis of computable phenotype of frailty rests on screening questions about ability to climb two flights of stairs, activities of daily living, living environment, wearing of dentures/hearing aids, and whether the patient uses assistive devices.

Exclusion Criteria:

* Reduced ejection fraction (≤50%) with or without prior history of myocardial infarction
* Acute coronary syndrome \<3 months
* Uncontrolled diabetes mellitus (HbA1C\>8)
* Uncontrolled hypertension (\>160/100mmHg, despite 3 antihypertensive medications)
* Nephrotic syndrome or eGFR \<30mL/min/1.73m2
* Cirrhosis
* Hepatitis B/C positive
* Elevated lived enzymes (AST/ALT\>3ULN
* Prior malignancy other than basal cell carcinoma
* History of ongoing, chronic or recurrent infectious disease
* Suspected/proven immunocompromised state
* Uncontrolled hyperlipidemia (fasting TG \>400 mg/dL (\>4.5 mmol/L) or total cholesterol \>300 mg/dL (\>7.8 mmol/L) despite maximum lipid lowering therapy
* Class IV HF symptoms

Primary outcomes:
measure: Change cardiopulmonary reserve capacity by improving peak VO2 with rapamycin
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Mandeep Singh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00567619: LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)
Official title: LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: GERD
Keywords: GERD
NIS
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2007-12-05
Enrollment: 900
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: Evaluate burden of disease in Patients with newly occurred upper GI symptoms related to GERD (symptom frequency \& severity, QoL, lifestyle modifications, self-medication) - baseline data according to GERD impact scale presenting to specialists, especially internists

- Evaluate effect of treatment with a acid suppressive therapy on these parameters: looking for improvement of symptom burden and quality of life according to the GERD impact sca


Eligibility criteria: Inclusion Criteria:

* Patients with newly occured upper GI symptoms related to GERD

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Research Site
Study officials:
affiliation: Not required for this study
name: Not required for Study
role: STUDY_CHAIR
References:
Clinical trial NCT04778319: Hysterosalpingography and Hysteroscopy in ICSI
Official title: Hysterosalpingography and Hysteroscopy in Intracytoplasmic Sperm Injection
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Infertility
Lead sponsor: Aljazeera Hospital
Sponsor class: OTHER
First posted: 2021-03-03
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: unexplained infertility is a rising problem in clinical practice

Detailed description: Assessment of uterine cavity is very important before ICSI

Eligibility criteria: Inclusion Criteria:

* women with infertility

Exclusion Criteria:

* women with medical disorders

Primary outcomes:
measure: the number of women who will become pregnant
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Aljazeera( Al Gazeera) hospital
Study officials:
affiliation: Algezeera hospitaland National Research Centre ,Egypt
name: Mahmoud Alalfy
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02108119: The Effect of Probiotics on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Irritable Bowel Syndrome
Lead sponsor: Probi AB
Sponsor class: INDUSTRY
First posted: 2014-04-09
Enrollment: 197
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To demonstrate benefit of a probiotic product in adults with irritable bowel syndrome.


Eligibility criteria: Inclusion Criteria:

* Willing and able to provide informed consent
* Age ≥18 and ≤70 years at Visit 1
* IBS according to the Rome III criteria
* A score on abdominal pain NRS ≥3 and ≤6 at least two days a week measured the weeks before Visit 2 (baseline)
* IBS-SSS ≥75 and ≤300 at Visit 2 (baseline)
* Ability and willingness to understand and comply with the study procedures

Exclusion Criteria:

* Known intolerance or allergy to milk products (protein or lactose) or gluten
* History of alcohol or substance abuse six months prior to screening
* Known Hepatitis B or C or Human Immunodeficiency Virus (HIV) 1 or 2
* Female patients: currently pregnant or breast-feeding or intending to become pregnant during the study
* Abnormal results of the screening laboratory tests clinically relevant for study participation, as judged by the Investigator
* Other gastrointestinal disease(s) that explains the patient's symptoms, as judged by the Investigator
* Other severe disease(s) such as malignancy, severe coronary disease, kidney disease or neurological disease, as judged by the Investigator
* Symptoms indicating other severe disease(s) such as gastrointestinal bleeding, loss of weight or fever, as judged by the Investigator
* Severe psychiatric disease as judged by the Investigator
* Lack of suitability for participation in the study for any reason as judged by the Investigator
* Use of other probiotic products from Visit 1 and throughout the study.
* Consumption of antibiotic drugs 1 month prior to screening and throughout the study.
* Consumption of drugs on a regular basis which could interfere with symptom evaluation as judged by the Investigator.

Primary outcomes:
measure: Abdominal pain
timeFrame: 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Beek
country: Netherlands
facility: PreCare Trial & Recruitment
Study officials:
References: